Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR8 | P51685 | 14/20 | 0.78 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.43 |
| ▸ | MMP1 | P03956 | 2/20 | 0.41 |
| ▸ | MMP9 | P14780 | 2/20 | 0.41 |
| ▸ | MMP13 | P45452 | 2/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6509148 | 0.88 | CCR8 (1.00) | CCR8KCNH2MMP1MMP9MMP13 | |
| SCHEMBL6501296 | 0.82 | CCR8 (0.86) | CCR8KCNH2MMP1MMP9MMP13 | |
| SCHEMBL6501070 | 0.80 | CCR8 (0.86) | CCR8KCNH2MMP1MMP9MMP13 | |
| SCHEMBL7070871 | 0.79 | CCR8 (0.84) | CCR8KCNH2MMP1MMP9MMP13 | |
| SCHEMBL7063399 | 0.79 | CCR8 (0.83) | CCR8KCNH2MMP1MMP9MMP13 | |
| SCHEMBL6505643 | 0.78 | CCR8 (0.78) | CCR8KCNH2MMP1MMP9MMP13 | |
| SCHEMBL6504810 | 0.77 | CCR8 (0.77) | CCR8KCNH2KMT2AMEN1MGLL | |
| SCHEMBL6496005 | 0.74 | CCR8 (0.73) | CCR8KCNH2MMP1MMP9MMP13 | |
| SCHEMBL6500877 | 0.73 | CCR8 (0.71) | CCR8KCNH2KMT2AMEN1POLB | |
| SCHEMBL6497194 | 0.73 | STS (0.44) | CCR8MMP1MMP9MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. | 2005-06-30 | — | — | US | disclosed |
| WO-2003037271-A2 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREFOR | MILLENNIUM PHARMACEUTICALS,INC. (US) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | CCR8, CCL11, CCR5 | CCR8 1/4885OPRM1 494/4885KCNH2 4349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.